Journal article
Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity
A Reyes-Sandoval, CS Rollier, A Milicic, K Bauza, MG Cottingham, CK Tang, MD Dicks, D Wang, RJ Longley, DH Wyllie, AVS Hill
Molecular Therapy | CELL PRESS | Published : 2012
DOI: 10.1038/mt.2012.25
Open access
Abstract
Substantial protection can be provided against the pre-erythrocytic stages of malaria by vaccination first with an adenoviral and then with an modified vaccinia virus Ankara (MVA) poxviral vector encoding the same ME.TRAP transgene. We investigated whether the two vaccine components adenovirus (Ad) and MVA could be coinjected as a mixture to enhance protection against malaria. A single-shot mixture at specific ratios of Ad and MVA (AdMVA) enhanced CD8 ++ T cell-dependant protection of mice against challenge with Plasmodium berghei. Moreover, the degree of protection could be enhanced after homologous boosting with the same AdMVA mixture to levels comparable with classic heterologous Ad prime..
View full abstractGrants
Awarded by Wellcome Trust
Funding Acknowledgements
We thank the Jenner Institute's vector core facility for providing the viral-vectored vaccines and Dr Helen McShane for providing the adenoviral and MVA vectors expressing antigen 85A. We are also grateful to Andrew Williams for providing the P. berghei parasites and the NIH tetramer facility (MHC tetramer core facility, Emory University Vaccine Center, Atlanta, GA) for preparing the Pb9 tetramer. The transgenic parasites were kindly provided by Dr Oliver Billker from Wellcome Trust Sanger Institute, Hinxton, UK. This work was funded by Wellcome Trust Principal Research Fellowship award; Grant Number: 076438; The National Institute for Health Research Oxford Biomedical Research Centre Program and Grand Challenges in Global Health. A.R.-S. is a Scientific Leadership Fellow of the Nuffield Department of Medicine and a Wellcome Trust Fellow. C. S. R. is supported by Oxford Biomedical Research Center, The Oxford Martin School and Meningitis UK.